venlafaxine (Effexor)

Subscribe to Selected New Research on venlafaxine

656 relevant articles (139 outcomes, 166 trials/studies) found for this Drug

Description: for the treatment of depression; a norepinephrine reuptake inhibitor; structure given in first source

Also Known As:

Effexor; Efexor; 1-(2-(dimethylamino)-1-(4-methoxyphenyl)ethyl)cyclohexanol HCl; AHP brand of venlafaxine hydrochloride; Almirall brand of venlafaxine hydrochloride; Cyclohexanol, 1-(2-(dimethylamino)-1-(4-methoxyphenyl)ethyl)-, hydrochloride; Dobupal; Trevilor; Vandral; Wy 45030; Wy-45,030; Wy-45030; Wyeth brand of venlafaxine hydrochloride; sila-venlafaxine; venlafaxine hydrochloride; 1-(2-dimethylamino-1-(4-methoxyphenyl)ethyl)cyclohexan-1-ol

Relationship Network

Drug Context: Research Results

Organic Chemicals: 40

Hydrocarbons: 382

Cyclic Hydrocarbons: 2

Alicyclic Hydrocarbons: 1

Experts

1.	Hackett, David: 8 articles (08/2004 - 01/2002)
2.	Stein, Dan J: 4 articles (09/2008 - 10/2005)
3.	Pae, Chi-Un: 4 articles (01/2008 - 08/2004)
4.	Mangano, Richard: 4 articles (10/2007 - 08/2004)
5.	Haudiquet, Vincent: 4 articles (09/2007 - 07/2002)
6.	Westenberg, Herman G M: 4 articles (05/2007 - 12/2003)
7.	Denys, Damiaan: 4 articles (05/2007 - 12/2003)
8.	Kunz, Nadia R: 4 articles (03/2007 - 05/2004)
9.	Salinas, E: 4 articles (11/2001 - 06/2000)
10.	Benattia, Isma: 3 articles (09/2008 - 06/2006)

Related Diseases

1.	Anxiety Disorders (Anxiety Disorder) 10/01/2005 - "BACKGROUND: Venlafaxine extended-release (ER) has proven efficacy in the treatment of anxiety symptoms in major depression, generalised anxiety disorder and social anxiety disorder" 01/01/2004 - "Venlafaxine is an alternative option, beneficial in depression, post-traumatic stress and generalised anxiety disorders" 01/01/2005 - "Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial." 01/01/2004 - "Patients with generalized anxiety disorder treated with venlafaxine XR showed similar absolute rates of response on somatic and psychic symptoms, but relative to patients treated with placebo, more improvement in psychic than somatic symptoms." 11/15/2007 - "CONCLUSIONS: Venlafaxine ER is an effective and reasonably well-tolerated treatment for generalized social anxiety disorder in children and adolescents" Order ALL the reference details at left...
2.	Major Depressive Disorder (Major Depressive Disorders) 04/01/2008 - "CONCLUSION: The present study indicates that maintenance treatment for 2 years with venlafaxine is cost-effective in patients with recurrent major depressive disorder." 07/01/2002 - "CONCLUSION: Venlafaxine IR/venlafaxine XR may be effective in outpatients with major depressive disorder who do not respond or have an unsustained response to SSRIs" 06/21/2000 - "Venlafaxine extended-release (XR) capsules have been shown to be effective in short-term treatment of patients with GAD without major depressive disorder (MDD), but long-term data are needed to establish whether this agent confers persistent benefits" 06/01/1996 - "The results from this analysis indicate that long-term treatment with venlafaxine in patients with major depressive disorder is effective in maintaining the initial response compared with placebo and suggest that venlafaxine will be effective in the prevention of relapse." 05/01/2004 - "Many studies have demonstrated that venlafaxine is an efficacious and safe treatment for major depressive disorder (MDD)" Order ALL the reference details at left...
3.	Pain (Aches) 03/01/2002 - "Venlafaxine (SNaRI), the most investigated of these new drugs, was shown to be effective in the treatment of different kinds of pain, with side-effects profile significantly better than TCAs" 04/01/2008 - "Venlafaxine proved to be beneficial in the treatment of both depressive symptoms and chronic pain" 01/01/2004 - "Pain relief was significantly greater with venlafaxine than with the placebo treatment" 03/01/2004 - "CONCLUSIONS: Extended release venlafaxine can be an effective and well-tolerated treatment in patients with chronic pain of any etiology, although it must be investigated in depth." 04/01/2008 - "This observational study aimed to elucidate the efficacy of venlafaxine and its prescription by Swiss primary care physicians and psychiatrists in patients with chronic pain and depressive symptomatology" Order ALL the reference details at left...
4.	Panic Disorder (Panic Attack) 09/01/1995 - "The efficacy of low doses of venlafaxine or the need to start treatment with very low doses in patients with panic disorder was predicted by experience with other monoamine reuptake inhibitors in this patient population" 10/01/2005 - "RESULTS: Venlafaxine ER was not associated with a greater proportion of patients free from full-symptom panic attacks at the final on-therapy evaluation, but was associated with lower mean panic attack frequency and a higher proportion free from limited-symptom panic attacks, higher response and remission rates, and improvements in anticipatory anxiety, fear and avoidance" 01/01/2007 - "CONCLUSION: Venlafaxine ER was safe, well tolerated, and effective in preventing relapse in outpatients with panic disorder." 09/01/1995 - "CONCLUSION: The resolution of panic disorder in all four patients treated with low doses of venlafaxine suggests that venlafaxine might be an effective treatment for panic disorder" 01/01/1996 - "We present what we believe are the first data from a controlled study designed to test the efficacy of venlafaxine for the treatment of panic disorder" Order ALL the reference details at left...
5.	Depressive Disorder (Melancholia) 04/01/2006 - "CONCLUSIONS: Venlafaxine ER was shown to be an effective and safe drug for the treatment of very elderly primary care patients with depressive syndrome and associated anxiety symptoms." 05/01/2006 - "CONCLUSION: In this study, venlafaxine extended release shows that it is an effective and safe drug in the treatment of the depressive-anxious symptoms of patients with depressive syndrome treated in primary care, both in remission and response rates" 05/01/2006 - "INTRODUCTION: The aim of this observational study was to evaluate the long term effect of treatment with venlafaxine extended release on response and remission in patients with depressive syndrome and associated anxiety symptoms, in primary health care" 06/01/1999 - "The study conducted by Guelfi, in France, in patients presenting with severe depression was designed to evidence the efficacy of venlafaxine in melancholia" 05/01/2008 - "The main objectives of this multicenter, naturalistic, open-label study is to evaluate the effectiveness, tolerability and safety of venlafaxine extended release (VXR) in a sample of 59 patients older than 60 years of age diagnosed of depressive disorders in the primary care setting" Order ALL the reference details at left...

Related Drugs and Biologics

1.	Serotonin (5 Hydroxytryptamine)
2.	Antidepressive Agents (Antidepressants)
3.	Paroxetine (Paxil)
4.	Norepinephrine (Noradrenaline)
5.	Fluoxetine (Prozac)
6.	Citalopram (Escitalopram)
7.	Serotonin Uptake Inhibitors (Serotonin Reuptake Inhibitors)
8.	Sertraline (Zoloft)
9.	duloxetine (Cymbalta)
10.	Bupropion (Wellbutrin)

Related Therapies and Procedures

1.	Home Nursing (Nursing, Home)
2.	Drug Therapy (Chemotherapy)
3.	Aftercare (After-Treatment)
4.	Metered Dose Inhalers (Metered Dose Inhaler)
5.	Withholding Treatment

Best Treatments:
Research Summary Report
on Anxiety Disorders

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 334 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>